Voyager Therapeutics & Genzyme collaborate to develop and commercialize novel AAV gene therapies for patients with CNS Disorders
13-Feb-2015 -
Voyager Therapeutics and Genzyme, a Sanofi company, today announced a major strategic collaboration to discover, develop and commercialize novel gene therapies for severe CNS disorders. The collaboration will leverage Genzyme’s commitment in the field of adeno-associated virus (AAV) gene therapy ...
CNS disorders
Friedreich's ataxia
Huntington's disease
+1